Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Novel ZetaMet™ Technology Discovered for Metastatic Bone Cancers

Zetagen Therapeutics, discovered novel ZetaMet™ technology for the treatment of metastatic bone cancers. This technology is the first to suspend cancer inhibit pain, and regenerate bone.

ZetaMet™ technology was earlier known as ZetaFuse. It is a synthetic, small-molecule, inductive biologic technology introduced to target and resolve metastatic bone lesions which restricts the further growth of tumor growth and regenerating bone.

ZetaMet™ is a novel and patented molecular pathway. The small molecule dosage is delivered with a proprietary drug-eluting carrier to the affected area which stimulates cells for the healthy bone growth known as “osteoblasts” and the growth of cells with bone degradation called “osteoclasts”.

Bone metastases are often found among cancer patients and occur when cells from primary cancerous tumor relocate to the bone. During the process of relocation, it can cause bone damage known as osteolysis.  Osteolysis causes small holes inside the bone thereby weakening it and increasing the risk of breakage. These holes are known as lytic lesions.

US Food and Drug Administration (FDA) has approved ZetaMet™ KYNMOBI™ for the treatment of metastatic bone cancers.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024